drugset

Drugs / MK-8690

Follow last change Mar 2026 re-read 3 minutes ago

MK-8690

Developed for: ulcerative colitis
Investigated by: Merck Sharp & Dohme LLC

Trials 1

today NCT07463183 · Ph 2

2027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT07463183	Mar 2026 → Oct 2027 expected	ulcerative colitis	Merck Sharp & Dohme LLC	Recruiting	No outcome recorded

Press releases naming this drug 2 releases

Date	Issuer	Release
2025-11-04	Merck Sharp & Dohme LLC	MSD Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody msd.com ↗
2025-11-04	Merck Sharp & Dohme LLC	Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody merck.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	MK-8690	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07463183 ↗
Route	Subcutaneous	“Participants will receive MK-8690 via subcutaneous injection for 12 weeks.” NCT07463183 ↗